In the present meta-analysis of nine RCTs totaling 54,311 patients, we evaluated the comparative effect of three PCSK9 inhibitors in the secondary prevention in patients with high-risk of ASCVD. This evidence concerns the gene PCSK9 and atherosclerosis.